Clinical Trials & Research Studies in United Kingdom(Updated 8/25)

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

NCT03695978

Recruiting

International, post-authorisation non-interventional study to evaluate real-life effectiveness, safety and utilisation patterns of Octapharma's FVIII concentrates Nuwiq, Octanate, and Wilate in previously untreated and minimally treated severe haemophilia A patients in routine clinical practice.

Gender:

ALL

Ages:

All

Trial Updated:

04/16/2025

Locations: Cure 4 The Kids Foundation Children's Specialty Center, Las Vegas, Nevada +45 locations

Cure 4 The Kids Foundation Children's Specialty Center, Las Vegas, Nevada

Azerbaijan State Advanced Training Institute for Doctors Hematology Department Scientific-Research Center of Hemophilia, Baku, Not set

Republican Scientific Center for Radiation Medicine and Human Ecology, Gomel, Not set

Republican Scientific and Practical Centre of Children Oncology, Hematology and Immunology, Minsk, Not set

Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Not set

Cliniques Universitaires Saint-Luc, Brussels, Not set

McMaster University, Division of Pediatric Hematology/Oncology Room 3N27, Hamilton, Ontario

Department of Hematology Research Research Transition Facility, Edmonton, Not set

University Hospital Centre Zagreb, Croatia, Not set

Tallinn Childrenś Hospital Clinic of Paediatric Department of Haematology and Oncology, Tallinn, Not set

CENTRE HOSPITALIER UNIVERSITAIRE de BESANCON, Besancon, Not set

Centre Régional de Traitement de l'hémophilie, Le Mans, Not set

Hopital Simone Veil Groupement Hospitalier Eaubonne-Montmorency, Montmorency, Not set

CHU Hotel Dieu, Centre de Traitment de l'Hemophilie, Nantes, Not set

Hôspital Necker Enfants Malades, Paris, Not set

CHRU Hopital Nord, Secretariat de pediatre, bat E niv +3, Saint-Priest-en-Jarez, Not set

Vivantes - Netzwerk für Gesundheit GmbH Klinikum im Friedrichshain, Berlin, Not set

Institute of Experimental Haematology and Transfusion Medicine (IHT) University Clinic Bonn (AöR), Bonn, Not set

Coagulation Research Centre GmbH, Duisburg, Not set

Heim Pál National Pediatric Institute Department of Oncology and Hematology, Budapest, Not set

University of Debrecen Department of Pediatrics, Debrecen, Not set

Ospedale Pediatrico "Giovani XXIII", Bari, Not set

Policlinico Sant'Orsola Malpighi, Bologna, Not set

Ospedale San Giacomo, Castelfranco Veneto, Not set

Azienda Ospedaliera-Universitaria Policlinico "Vittorio Emanuele", Centro di Riferimento Regionale per la Prevenzione, Diagnosi e Cura delle Malattie Rare della Coagulazione nel Bambino e neel'Adulto. U.O.C Ematologia con trapianto di Midollo Osseo, Catania, Not set

Azienda Ospedaliero Universitaria Careggi, Florence, Not set

Ospedale Maggiore Policlinico, Milan, Not set

Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Milan, Not set

Centro Emofilia - AUO di Padova, Padova, Not set

Policlinico Umberto I, Rome, Not set

C.tro Emofilia A.O. Città della salute e della scienza di Torino, Ospedale Regina Margherita, Torino, Not set

Ospedale Regina Margherita, Turin, Not set

Children's Hospital Affiliate of Vilnius Universtity Hospital Santaros Klinikos, Vilnius, Not set

Hospital Infantil de Morelia Eva Sámano de López Mateos, Morelia, Not set

Hospital Universitario Dr. José Eleuterio Gonzalez S/N, Nuevo León, Not set

SMO and Scientific Services S.A.P.P de C.V, Nuevo León, Not set

Moscow State Government-financed Public Healthcare Institution "Morozovskaya Children Clinical Hospital of Moscow Healthcare Department", Moscow, Not set

Saint-Petersburg State Budget Healthcare Institution "City Out-patient Clinical # 37", Saint Petersburg, Not set

Hospital General Universitario de Alicante Hematología y Hemoterapia, Alicante, Not set

Hospital Universitari Vall D'Hebrón, Unitat d'Hemofilia, Barcelona, Not set

Istanbul University Faculty of Medicine, Fatih, Not set

John Radcliffe Hospital, Oxford University Hospitals, NHS Foundation Trust, Headington, Oxford

Birmingham Children's Hospital NHS Foundation Trust, Birmingham, Not set

Great Ormond Street Hospital for Children NHS Trust, Haemophilia Centre, London, Not set

Newcastle Haemophilia Comprehensive Care Centre, Royal Victoria Infirmary, Newcastle Upon Tyne, Not set

Conditions: Haemophilia A

Register for Updates

Learn More ›

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

NCT05936580

Recruiting

Recombinant factor VIII for the prevention of bleeding in women/girls with haemophilia A undergoing major surgery

Gender:

FEMALE

Ages:

12 years and above

Trial Updated:

04/16/2025

Locations: UT Health San Antonio, San Antonio, Texas +12 locations

Conditions: Hemophilia A

Register for Updates

Learn More ›

AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion

NCT06029660

Recruiting

To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/16/2025

Locations: University of Alabama Birmingham, Birmingham, Alabama +34 locations

University of Alabama Birmingham, Birmingham, Alabama

Honor Health, Scottsdale, Arizona

USC Keck, Los Angeles, California

Delray Medical Center, Delray Beach, Florida

Orlando Health, Orlando, Florida

Emory University Hospital, Atlanta, Georgia

University of Chicago, Chicago, Illinois

Indiana University, Indianapolis, Indiana

Maine Medical, Portland, Maine

Massachusetts General Hospital, Boston, Massachusetts

Brigham & Women's Hospital, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Corewell Health, Grand Rapids, Michigan

Mayo Clinic, Rochester, Minnesota

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Buffalo VA Western New York, Buffalo, New York

NYU Langone, New York, New York

Columbia University Medical Center, New York, New York

University of Rochester, Rochester, New York

TriHealth Heart Institute, Cincinnati, Ohio

Ohio State University Wexner Medical Center, Columbus, Ohio

The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Sanford Health, Sioux Falls, South Dakota

Vanderbilt University, Nashville, Tennessee

Houston Methodist, Houston, Texas

Baylor Scott and White, Plano, Texas

Inova Schar Heart and Vascular, Falls Church, Virginia

Sentara Norfolk General, Norfolk, Virginia

University of Wisconsin, Madison, Wisconsin

Marie Lannelongue Hospital, Paris, Le Plessis-Robinson

Rijnstate Hospital, Arnhem, Gelderland

Amsterdam UMC, Amsterdam, Not set

ETZ Elisabeth, Tilburg, Not set

Auckland City Hospital, Auckland, Not set

St Georges University Hospitals NHS Foundation Trust, London, Not set

Conditions: Aortic Aneurysm, Abdominal

Register for Updates

Learn More ›

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

NCT05935358

Recruiting

Recombinant factor VIII for the prevention of bleeding in patients with severe haemophilia A undergoing major surgery while receiving emicizumab prophylaxis

Gender:

MALE

Ages:

12 years and above

Trial Updated:

04/16/2025

Locations: UT Southwestern Medical Center, Dallas, Texas +17 locations

Conditions: Severe Hemophilia A

Register for Updates

Learn More ›

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT06343779

Recruiting

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in participants ≥12 to ≤75 years of age with HAE type 1, type 2, or type 3, a proportion of whom are using long-term prophylactic medication for HAE.

Gender:

ALL

Ages:

Between 12 years and 75 years

Trial Updated:

04/16/2025

Locations: Study Site, Birmingham, Alabama +75 locations

Study Site, Birmingham, Alabama

Study Site, Paradise Valley, Arizona

Study Site, Little Rock, Arkansas

Study Site, San Diego, California

Study Site, Santa Monica, California

Study Site, Walnut Creek, California

Study Site, Colorado Springs, Colorado

Study Site, Chevy Chase, Maryland

Study Site, Boston, Massachusetts

Study Site, Detroit, Michigan

Study Site, Saint Louis, Missouri

Study Site, Hershey, Pennsylvania

Study Site, Dallas, Texas

Study Site, Buenos Aires, Not set

Study Site, Salta, Not set

Study Site, Campbelltown, New South Wales

Study Site, Box Hill, Not set

Study Site, Graz, Not set

Study Site, Linz, Not set

Study Site, Wien, Not set

Study Site, Paraná, Not set

Study Site, Ribeirão Preto, Not set

Study Site, Salvador, Not set

Study Site, Santo André, Not set

Study Site, São Paulo, Not set

Study Site, Sofia, Not set

Study Site, Edmonton, Alberta

Study Site, Bogotá, Not set

Study Site, Medellín, Not set

Study Site, Brno, Not set

Study Site, Lille, Not set

Study Site, Paris, Not set

Study Site, Berlin, Not set

Study Site, Frankfurt am Main, Not set

Study Site, Lubeck, Not set

Study Site, Hong Kong, Not set

Study Site, Budapest, Not set

Study Site, Dublin, Not set

Study Site, Catania, Not set

Study Site, Milano, Not set

Study Site, Milan, Not set

Study Site, Padova, Not set

Study Site, Palermo, Not set

Study Site, Roma, Not set

Study Site, Chiba-city, Not set

Study Site, Hiroshima, Not set

Study Site, Kanagawa, Not set

Study Site, Osaka, Not set

Study Site, Tokyo, Not set

Study Site, Daegu, Not set

Study Site, Seoul, Not set

Study Site, Amsterdam, Not set

Study Site, Skopje, Not set

Study Site, Kraków, Not set

Study Site, San Juan, Not set

Study Site, Sângeorgiu De Mureş, Not set

Study Site, Riyadh, Not set

Study Site, Singapore, Not set

Study Site, Cape Town, Not set

Study Site, Barcelona, Not set

Study Site, Lund, Not set

Study Site, Ankara, Not set

Study Site, Istanbul, Not set

Study Site, İzmir, Not set

Study Site, Bristol, Not set

Study Site, Camberley, Not set

Study Site, Cambridge, Not set

Study Site, Leeds, Not set

Study Site, London, Not set

Study Site, Plymouth, Not set

Conditions: Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema - Type 3, Hereditary Angioedema Type III

Register for Updates

Learn More ›

A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant

NCT04006808

Recruiting

The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2 doses of PED-HZ/su, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in immunocompromised paediatric renal transplant recipients aged 1-17 years

Gender:

ALL

Ages:

Between 1 year and 17 years

Trial Updated:

04/16/2025

Locations: GSK Investigational Site, Bruxelles, Not set +30 locations

GSK Investigational Site, Bruxelles, Not set

GSK Investigational Site, Gent, Not set

GSK Investigational Site, Leuven, Not set

GSK Investigational Site, Liege, Not set

GSK Investigational Site, Bordeaux cedex, Not set

GSK Investigational Site, Lille, Not set

GSK Investigational Site, Marseille cedex 5, Not set

GSK Investigational Site, Montpellier cedex, Not set

GSK Investigational Site, Nantes, Not set

GSK Investigational Site, Paris, Not set

GSK Investigational Site, Toulouse cedex 9, Not set

GSK Investigational Site, Genova, Not set

GSK Investigational Site, Milano, Not set

GSK Investigational Site, Padova, Not set

GSK Investigational Site, Roma, Not set

GSK Investigational Site, Torino, Not set

GSK Investigational Site, Gdansk, Not set

GSK Investigational Site, BaracaldoVizcaya, Not set

GSK Investigational Site, Espluges De Llobregat, Not set

GSK Investigational Site, HebrOn, Not set

GSK Investigational Site, Madrid, Not set

GSK Investigational Site, Sevilla, Not set

GSK Investigational Site, Birmingham, Not set

GSK Investigational Site, Cardiff, Not set

GSK Investigational Site, Glasgow Strathclyde, Not set

GSK Investigational Site, London, Not set

GSK Investigational Site, Manchester, Not set

GSK Investigational Site, Nottingham, Not set

GSK Investigational Site, Southampton, Not set

Conditions: Herpes Zoster

Register for Updates

Learn More ›

Monitoring Key Activity and Physiology of Neonates in Intensive Care

NCT04831242

Recruiting

To optimise and evaluate a novel non-contact physiological monitoring system in the neonatal intensive care unit (NICU)

Gender:

ALL

Ages:

All

Trial Updated:

04/15/2025

Locations: Addenbrookes Hospital, Cambridge, Not set

Conditions: Neonatal Seizure

Register for Updates

Learn More ›

Short-term Effect of Using Non-immersive Gamified Exercises on Chronic Pain in People With Stroke.

NCT06863649

Recruiting

Rehabilitation after stroke is essential to minimize permanent disability. Gamification of exercises has emerged as a promising strategy for increasing motivation and rehabilitation efficacy in people with stroke. However, there is a gap in understanding how exercise gamification can aid in pain management among people with stroke who are experiencing shoulder pain difficulties. This study aims to evaluate the short-term effect of using gamified non-immersive exercises on shoulder pain level, u... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/15/2025

Locations: Vsimulator, Exeter, Devon

Conditions: Stroke Patients

Register for Updates

Learn More ›

Validating Novel, Non-contrast Cardiac MRI Imaging in Haemodialysis Patients

NCT03586518

Recruiting

There are currently no good ways of measuring levels of scarring in the hearts of patients with advanced kidney disease and patients on dialysis, although recent research has shown a new cardiac MRI technique, called native T1 mapping, may provide a solution to this. To assess the accuracy of this novel technique in dialysis patients, it is essential to undertake a study which compares native T1 mapping to actual levels of scarring in the hearts of patients on dialysis.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/15/2025

Locations: University Hospitals of Leicester NHS Trust, Leicester, Leicestershire

Conditions: End Stage Kidney Disease, Fibrosis Myocardial

Register for Updates

Learn More ›

International Study of Cerebral Oxygenation and Electrical Activity During Major Neonatal Surgery

NCT05673499

Recruiting

The goal of this observational study is to determine the incidence of perioperative cerebral desaturation in neonates undergoing surgery for congenital malformations. The main questions it aims to answer are: 1. The perioperative factors associated with occurrence of cerebral desaturation 2. The association between perioperative cerebral desaturation, perioperative/hospital outcomes, and physiological conditions. Participants will undergo Near-infrared spectroscopy (NIRS) and electroencephalog... Read More

Gender:

ALL

Ages:

60 weeks and below

Trial Updated:

04/15/2025

Locations: Children's Hospital at Montefiore/Albert Einstein College of Medicine, New York, New York +14 locations

Conditions: Congenital Disorders, Cerebral Desaturation, Neonatal Surgery

Register for Updates

Learn More ›

CuePD: Investigating the Effect of Personalised Auditory Cueing on Gait in Parkinson's Disease

NCT06941779

Recruiting

Parkinson's Disease (PD) is a major cause of disability, globally. PD affects a person's movement speed, fluency, quality, and ease of walking. PD has the fastest-growing incidence rate, with its prevalence expected to double over the next three decades, currently affecting 10 million people worldwide. PD often leads to disturbances in walking/gait characteristics such as abnormal/variable stride lengths and step times. Those disturbances increase the risk of falls, with about 39% of people with... Read More

Parkinson's Disease (PD) is a major cause of disability, globally. PD affects a person's movement speed, fluency, quality, and ease of walking. PD has the fastest-growing incidence rate, with its prevalence expected to double over the next three decades, currently affecting 10 million people worldwide. PD often leads to disturbances in walking/gait characteristics such as abnormal/variable stride lengths and step times. Those disturbances increase the risk of falls, with about 39% of people with PD (PwPD) experiencing an average of 20.8 falls/year. Research has examined cueing by leveraging auditory, visual, and tactile cues to normalize variable gait characteristics and improve mobility to reduce falls. Auditory cueing is the most effective at improving gait and most practical to apply in all settings (via headphones) but one size does not fit all when using auditory cueing paradigms i.e., there is a need for personalised approaches to ensure cueing interventions are tailored to the individual and their specific functional limitations. Furthermore, the long-term effectiveness of auditory mechanisms (e.g., metronome-based repetitive beep) suffer from their lack of continuous engagement. This research project aims to examine personalised auditory cueing to improve gait in PwPD. Inertial sensors will capture and analyze validated gait-related characteristics and personalised auditory cues will be examined for their ability to correct variable gait. To reduce burden on PwPD (i.e., minimal number of wearable sensors) and to streamline data capture and deliver auditory cues, a single smartphone will be used only. The project involves a multidisciplinary study between Computing and Exercise and Rehabilitation at Northumbria University, testing cueing modalities in a controlled laboratory environment under trained researcher supervision. The study will enrol PwPD, focusing on the ability of personalised auditory cueing to improve gait and PwPD preference of auditory cues. Read Less

Gender:

ALL

Ages:

Between 50 years and 85 years

Trial Updated:

04/15/2025

Locations: Northumbria University, Newcastle, Not set +1 locations

Conditions: Parkinson's Disease (PD)

Register for Updates

Learn More ›

Multicenter Glaucoma Study Investigating Standalone Canaloplasty

NCT05786196

Recruiting

A multicenter, randomized, clinical trial to evaluate the efficacy of canaloplasty performed as a standalone procedure using the iTrack™ Advance canaloplasty device (Nova Eye, Inc.) as compared to the OMNI® Surgical System (Sight Sciences) in patients with mild to moderate primary open-angle glaucoma.

Gender:

ALL

Ages:

22 years and above

Trial Updated:

04/15/2025

Locations: Breyer Kaymak Klabe Augenchirurgie, Düsseldorf, Not set +4 locations

Conditions: Primary Open Angle Glaucoma

Register for Updates

Learn More ›

All Clinical Trials in United Kingdom

Match to Clinical Trials